Christopher D. Ozeroff
Net Worth
Last updated:
What is Christopher D. Ozeroff net worth?
The estimated net worth of Mr. Christopher D. Ozeroff is at least $5,787,783 as of 22 Nov 2021. He owns shares worth $126,406 as insider, has earned $15,677 from insider trading and has received compensation worth at least $5,645,700 in ARCA biopharma, Inc..
What is the salary of Christopher D. Ozeroff?
Mr. Christopher D. Ozeroff salary is $376,380 per year as Senior Vice President, Gen. Counsel & Sec. in ARCA biopharma, Inc..
How old is Christopher D. Ozeroff?
Mr. Christopher D. Ozeroff is 66 years old, born in 1959.
What stocks does Christopher D. Ozeroff currently own?
As insider, Mr. Christopher D. Ozeroff owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| ARCA biopharma, Inc. (ABIO) | Senior Vice President, Gen. Counsel & Sec. | 50,970 | $2.48 | $126,406 |
What does ARCA biopharma, Inc. do?
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.
Christopher D. Ozeroff insider trading
ARCA biopharma, Inc.
Mr. Christopher D. Ozeroff has made 6 insider trades between 2010-2021, according to the Form 4 filled with the SEC. Most recently he purchased 50,000 units of ABIO stock worth $113,200 on 22 Nov 2021.
The largest trade he's ever made was exercising 50,000 units of ABIO stock on 22 Nov 2021. As of 22 Nov 2021 he still owns at least 50,970 units of ABIO stock.
ARCA biopharma key executives
ARCA biopharma, Inc. executives and other stock owners filed with the SEC:
- Dr. Michael R. Bristow M.D., Ph.D. (80) Co-Founder, Pres, Chief Executive Officer & Director
- Mr. Christopher D. Ozeroff (66) Senior Vice President, Gen. Counsel & Sec.
- Mr. Thomas A. Keuer (66) Chief Operating Officer